liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE)
National Hospital Norway, Norway.
National Hospital Norway, Norway.
Sahlgrens University Hospital, Sweden.
Rigshosp, Denmark.
Show others and affiliations
2017 (English)In: Clinical Transplantation, ISSN 0902-0063, E-ISSN 1399-0012, Vol. 31, no 9, e13038Article in journal (Refereed) Published
Abstract [en]

The Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial was a 12month, randomized, open-label, parallel-group trial that compared everolimus (EVR; n=56) to conventional CsA (n=59) immunosuppression. Previously, we reported that EVR outperformed CsA in improving renal function and coronary artery vasculopathy, despite a higher rejection rate with EVR. This study aimed to compare the effects of these treatments on quality of life (QoL). Within five post-operative days, patients (mean age 50 +/- 13years, 27% women) were randomized to EVR or a standard CsA dosage (CsA group). This study assessed quality of life (QoL), based on the Short Form-36, EuroQol-5D, and Beck Depression Inventory (BDI). Assessments were performed pre-HTx and 12 and 36months post-HTx. At 12 and 36months, the groups showed similar improvements in Short Form-36 measures (at pre-HTx, 12 and 36months the values were as follows: Physical component summary: EVR: 31.5 +/- 110.9, 49.1 +/- 9.7, and 47.9 +/- 10.6; Pamp;lt;.01; CsA: 32.5 +/- 8.2, 48.4 +/- 8.5, and 46.5 +/- 11.5; Pamp;lt;.01; mental component summary: EVR: 46.0 +/- 12.0, 51.7 +/- 11.9, and 52.1 +/- 13.0; Pamp;lt;.01; CsA: 38.2 +/- 12.5, 53.4 +/- 7.1, and 54.3 +/- 13.0; Pamp;lt;.01); similar decrease in mean BDI (EVR: 10.9 +/- 10.2, 5.4 +/- 4.7, and 8.1 +/- 9.0; Pamp;lt;.01; CsA: 11.8 +/- 7.1, 6.3 +/- 5.4, and 6.2 +/- 6.5; Pamp;lt;.01); and similar Euro Qol-improvements. Thus, in this small-sized study, EVR-based and conventional CsA immunosuppressive strategies produced similar QoL improvements.

Place, publisher, year, edition, pages
WILEY , 2017. Vol. 31, no 9, e13038
Keyword [en]
heart transplantation; immunosuppression; quality of life
National Category
Surgery
Identifiers
URN: urn:nbn:se:liu:diva-141127DOI: 10.1111/ctr.13038ISI: 000408913700009PubMedID: 28640529OAI: oai:DiVA.org:liu-141127DiVA: diva2:1144755
Available from: 2017-09-27 Created: 2017-09-27 Last updated: 2017-09-27

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Jansson, Kjell
By organisation
Division of Cardiovascular MedicineFaculty of Health SciencesDepartment of Cardiology in Linköping
In the same journal
Clinical Transplantation
Surgery

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 2 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf